Metastatic Liver Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：76頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Metastatic Liver Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Metastatic Liver Cancer - Pipeline Review, H1 2014’, provides an overview of the Metastatic Liver Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Metastatic Liver Cancer - Pipeline Review, H1 2014’, provides an overview of the Metastatic Liver Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Liver Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Liver Cancer - Overview 7
Pipeline Products for Metastatic Liver Cancer - Comparative Analysis 8
Metastatic Liver Cancer - Therapeutics under Development by Companies 9
Metastatic Liver Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Metastatic Liver Cancer - Products under Development by Companies 13
Metastatic Liver Cancer - Companies Involved in Therapeutics Development 14
F. Hoffmann-La Roche Ltd. 14
Celsion Corporation 15
Tekmira Pharmaceuticals Corp. 16
Arrowhead Research Corporation 17
Provectus Biopharmaceuticals, Inc. 18
Transgene Biotek Limited 19
Mirna Therapeutics, Inc. 20
PreScience Labs, LLC 21
Metastatic Liver Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
RG-7686 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
rose bengal sodium - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MRX-34 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TKM-PLK1 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PSL-001 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
doxorubicin liposomal - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TBL-0404 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Peptide Drug Conjugate For Metastatic Liver Cancer - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Metastatic Liver Cancer - Recent Pipeline Updates 44
Metastatic Liver Cancer - Dormant Projects 66
Metastatic Liver Cancer - Discontinued Products 67
Metastatic Liver Cancer - Product Development Milestones 68
Featured News & Press Releases 68
Oct 24, 2013: Provectus Awarded PV-10 Patent by U.S. Patent and Trademark Office 68
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 68
Sep 27, 2012: Provectus Pharma Expands Protocol For Phase I Liver Cancer Study 70
Aug 15, 2012: Delcath Submits New Drug Application For Chemosaturation System To FDA 70
Jun 07, 2012: Celsion To Begin Clinical Study Of ThermoDox For Metastatic Liver Cancer In Collaboration With University Of Oxford 71
Jun 05, 2012: Delcath Systems Presents Post-Hoc Analysis From Phase III Study Of Melphalan 72
Mar 02, 2010: Celsion Plans To Launch Phase II Program To Study ThermoDox In Combination With RFA For Colorectal Liver Metastases 73
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 73
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76
List of Tables
Number of Products under Development for Metastatic Liver Cancer, H1 2014 7
Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Metastatic Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 14
Metastatic Liver Cancer - Pipeline by Celsion Corporation, H1 2014 15
Metastatic Liver Cancer - Pipeline by Tekmira Pharmaceuticals Corp., H1 2014 16
Metastatic Liver Cancer - Pipeline by Arrowhead Research Corporation, H1 2014 17
Metastatic Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2014 18
Metastatic Liver Cancer - Pipeline by Transgene Biotek Limited, H1 2014 19
Metastatic Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2014 20
Metastatic Liver Cancer - Pipeline by PreScience Labs, LLC, H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 26
Number of Products by Stage and Route of Administration, H1 2014 28
Number of Products by Stage and Molecule Type, H1 2014 30
Metastatic Liver Cancer Therapeutics - Recent Pipeline Updates, H1 2014 44
Metastatic Liver Cancer - Dormant Projects, H1 2014 66
Metastatic Liver Cancer - Discontinued Products, H1 2014 67
List of Figures
Number of Products under Development for Metastatic Liver Cancer, H1 2014 7
Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Top 10 Route of Administration, H1 2014 27
Number of Products by Stage and Top 10 Route of Administration, H1 2014 28
Number of Products by Top 10 Molecule Type, H1 2014 29
Number of Products by Stage and Top 10 Molecule Type, H1 2014 30
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Liver Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Liver Cancer - Overview 7
Pipeline Products for Metastatic Liver Cancer - Comparative Analysis 8
Metastatic Liver Cancer - Therapeutics under Development by Companies 9
Metastatic Liver Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Metastatic Liver Cancer - Products under Development by Companies 13
Metastatic Liver Cancer - Companies Involved in Therapeutics Development 14
F. Hoffmann-La Roche Ltd. 14
Celsion Corporation 15
Tekmira Pharmaceuticals Corp. 16
Arrowhead Research Corporation 17
Provectus Biopharmaceuticals, Inc. 18
Transgene Biotek Limited 19
Mirna Therapeutics, Inc. 20
PreScience Labs, LLC 21
Metastatic Liver Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
RG-7686 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
rose bengal sodium - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MRX-34 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TKM-PLK1 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PSL-001 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
doxorubicin liposomal - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TBL-0404 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Peptide Drug Conjugate For Metastatic Liver Cancer - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Metastatic Liver Cancer - Recent Pipeline Updates 44
Metastatic Liver Cancer - Dormant Projects 66
Metastatic Liver Cancer - Discontinued Products 67
Metastatic Liver Cancer - Product Development Milestones 68
Featured News & Press Releases 68
Oct 24, 2013: Provectus Awarded PV-10 Patent by U.S. Patent and Trademark Office 68
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 68
Sep 27, 2012: Provectus Pharma Expands Protocol For Phase I Liver Cancer Study 70
Aug 15, 2012: Delcath Submits New Drug Application For Chemosaturation System To FDA 70
Jun 07, 2012: Celsion To Begin Clinical Study Of ThermoDox For Metastatic Liver Cancer In Collaboration With University Of Oxford 71
Jun 05, 2012: Delcath Systems Presents Post-Hoc Analysis From Phase III Study Of Melphalan 72
Mar 02, 2010: Celsion Plans To Launch Phase II Program To Study ThermoDox In Combination With RFA For Colorectal Liver Metastases 73
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 73
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76
List of Tables
Number of Products under Development for Metastatic Liver Cancer, H1 2014 7
Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Metastatic Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 14
Metastatic Liver Cancer - Pipeline by Celsion Corporation, H1 2014 15
Metastatic Liver Cancer - Pipeline by Tekmira Pharmaceuticals Corp., H1 2014 16
Metastatic Liver Cancer - Pipeline by Arrowhead Research Corporation, H1 2014 17
Metastatic Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2014 18
Metastatic Liver Cancer - Pipeline by Transgene Biotek Limited, H1 2014 19
Metastatic Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2014 20
Metastatic Liver Cancer - Pipeline by PreScience Labs, LLC, H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 26
Number of Products by Stage and Route of Administration, H1 2014 28
Number of Products by Stage and Molecule Type, H1 2014 30
Metastatic Liver Cancer Therapeutics - Recent Pipeline Updates, H1 2014 44
Metastatic Liver Cancer - Dormant Projects, H1 2014 66
Metastatic Liver Cancer - Discontinued Products, H1 2014 67
List of Figures
Number of Products under Development for Metastatic Liver Cancer, H1 2014 7
Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Top 10 Route of Administration, H1 2014 27
Number of Products by Stage and Top 10 Route of Administration, H1 2014 28
Number of Products by Top 10 Molecule Type, H1 2014 29
Number of Products by Stage and Top 10 Molecule Type, H1 2014 30
